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In type 1 diabetes, diabetes-associated autoantibodies, including
islet cell antibodies (ICAs), reﬂect adaptive immunity, while
increased serum N´-carboxymethyl-lysine (CML), an advanced
glycation end product, is associated with proinﬂammation. We
assessed whether serum CML and autoantibodies predicted type 1
diabetes and to what extent they were determined by genetic
or environmental factors. Of 7,287 unselected schoolchildren
screened, 115 were ICA+ and were tested for baseline CML and
diabetes autoantibodies and followed (for median 7 years),
whereas a random selection (n = 2,102) had CML tested. CML
and diabetes autoantibodies were determined in a classic twin
study of twin pairs discordant for type 1 diabetes (32 monozy-
gotic, 32 dizygotic pairs). CML was determined by enzyme-
linked immunosorbent assay, autoantibodies were determined
by radioimmunoprecipitation, ICA was determined by indirect
immunoﬂuorescence, and HLA class II genotyping was deter-
mined by sequence-speciﬁc oligonucleotides. CML was in-
creased in ICA+ and prediabetic schoolchildren and in diabetic
and nondiabetic twins (all P , 0.001). Elevated levels of CML in
ICA+ children were a persistent, independent predictor of dia-
betes progression, in addition to autoantibodies and HLA risk. In
twins model ﬁtting, familial environment explained 75% of CML
variance, and nonshared environment explained all autoanti-
body variance. Serum CML, a glycotoxin, emerged as an envi-
ronmentally determined diabetes risk factor, in addition to
autoimmunity and HLA genetic risk, and a potential therapeutic
target. Diabetes 61:1192–1198, 2012
A utoimmune diseases affect ;10% of the popu-lation and result from the interaction of geneticand nongenetic (probably environmental) fac-tors (1). Type 1 diabetes is a prototypic auto-
immune disease due to immune-mediated destruction of
insulin-secreting islet cells involving cells of both the in-
nate and adaptive immune systems (2,3). However, not all
genetically susceptible individuals develop type 1 diabetes;
consequently, even identical twins often remain discor-
dant for the disease (2–5). A limited number of predictive
biomarkers are associated with risk of diabetes, including
genetic features (i.e., HLA polymorphisms) and endo-
phenotypes (i.e., reduced insulin secretory capacity and
diabetes-associated autoantibodies) (2,3). The latter in-
clude islet cell antibodies (ICAs), serum autoantibodies
to GAD antibody (GADA), insulinoma-associated protein
2 antigen (IA-2A), and zinc transporter 8 (ZnT8A) (6–10).
In addition, there are innate immune changes involving al-
tered monocyte/macrophage and proinﬂammatory respon-
ses (11,12), with the latter including increased advanced
glycation end products (AGEs) (13). In normal physiology,
AGEs, such as N´-carboxymethyl-lysine (CML), are gener-
ated endogenously and can be strongly inherited, (14) but
tissue and serum AGE levels also relate to exogenous in-
testinal sources, especially heat-treated dietary factors (13).
Since both increased serum levels of CML and serum
autoantibodies are associated with type 1 diabetes, we
sought to discover whether each is genetically or envi-
ronmentally determined and antedates the disease. We,
therefore, performed a population-based cohort study to
ascertain whether this marker panel predicted diabetes.
Having established that CML and diabetes-associated
autoantibodies were predictive of type 1 diabetes, we
then performed a twin study on a cohort of monozygotic
(MZ) and dizygotic (DZ) pairs initially discordant for type
1 diabetes to investigate and control for potential con-
founding effects on these predictors of the disease itself
(cotwin case-control design) and to determine the impact
of genetic and environmental factors on them (classic
twin design).
RESEARCH DESIGN AND METHODS
Participants
Population study.We screened 7,287 unselected school children of European
origin between 1989 and 2008 in Germany. Of these, 115 participants (51.3%
women) who were ICA+ at ascertainment were followed for diabetes
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development (15–17). Baseline serum CML was tested in these 115 ICA+ subjects
and a random selection (n = 2,102) of the remainder of the sample. Moreover, in
the 115 ICA+ subjects, GADA and IA-2A were tested, and depending on serum
availability, ZnT8A was tested (n = 75) (Table 1) (16). Of 115 ICA+ subjects, 73
had.1 CML measurement prediabetes, the ﬁnal sample (CMLlast visit) being 5–10
months prediagnosis. All subjects gave informed consent, and the study was
approved by the ethical committee of the University Medical Center Ulm.
Twin study. A cohort of MZ and DZ twins were tested for serum CML and
diabetes-associated autoantibodies (GADA, IA-2A, and ZnT8A) to establish if
they were genetically determined. Twin pairs were selected from the British
Diabetic Twin Study and ascertained by referral through their physicians from
1971 to present (4,5). From our collection of 546 twin pairs, we identiﬁed all 32
initially disease-discordant DZ twin pairs and ascertained 32 MZ pairs dis-
cordant for type 1 diabetes of similar age at diagnosis and disease duration at
sampling (Table 2). These subjects fulﬁlled the following criteria: 1) European
origin, 2) twin pairs initially disease discordant, 3) both twins available for
study, 4) neither twin receiving drugs other than human insulin, 5) all had
normal plasma creatinine, 6) diabetes initially excluded in the cotwin by oral
glucose tolerance test and random whole blood glucose ,7.0 mmol/L. Zygosity
was determined as described previously (4), and type 1 diabetes was deﬁned by
standard criteria (15). As controls for serum CML, we tested 168 nondiabetic
female twins (39 MZ, 45 DZ pairs, mean age 51.3 [SD = 14.1], range 21–73) (14).
All subjects gave informed consent, and the East London Health Authority
Research Ethics Committee approved the study (Ref 07/Q0604/10).
CML assay. Serum samples were tested for the protein- and lipid-derived
stable glycoxidative product, CML. CML is a dominant circulating AGE, the best
characterized of all the AGEs. CML was measured using a competitive ELISA
(AGE-CML ELISA; MicroCoat, Penzberg, Germany), which is based on a CML-
speciﬁc monoclonal antibody and a glycated and biotinylated BSA coated to
a streptavidin microplate (18). This assay has been validated, is speciﬁc, and
shows no cross-reactivity with other compounds. CML levels are reported as
monomeric epitopes in nanogram per milliliter serum, irrespective of the
TABLE 1





(n = 82) P value
Age at inclusion (years), mean (SD) and [range] 13.48 (4.07) [6–19] 14.24 (4.01) [6–19] NS
Follow-up (months) 77 [58–115] 94 [67–130] NS
CMLinclusion (ng/mL) 669 [524–761] 512 [424–619] ,0.001
CMLlast visit (ng/mL)
a 773 [611–831] 424 [381.5–452] ,0.001
Male 18 (54.5) 38 (46.3) NS
Antibody positivity
GADA 29 (87.9) 57 (69.5) 0.04
IA-2A 17 (51.5) 14 (17.1) ,0.001
ZnT8Ab 21 (80.8) 14 (28.6) ,0.001
HLA risk status
Lowc 3 (11.1) 20 (40.8)
Highc 24 (88.9) 29 (59.2) 0.007
Of 7,287 normal subjects, 115 were ICA+ and 33 developed type 1 diabetes (T1D). Data are median [interquartile range] or n (%) unless
otherwise indicated. an = 25 T1D, n = 48 no T1D. bn = 26 T1D, n = 49 no T1D. cn = 27 T1D, n = 49 no T1D: high HLA risk status means that
subjects had any of the DRB1*03, DRB1*04, and/or DQB1*302 alleles.
TABLE 2
Characteristics of 32 MZ and 32 DZ twin pairs in the twin study
Twin study Diabetic twin
Nondiabetic
cotwin
MZ (n) 32 32
Male, n (%) 20 (62.5) 20 (62.5)
Age at sampling (years) 28.09 (16.41) 28.09 (16.41)
Duration of follow-up (years) 26.9 (11) 26.9 (11)
Age at diagnosis (years) 17.06 (12.32) NA





Serum CML (ng/mL), median [interquartile range] 2,638.5 [1,911.5–3,550.5] 2,248.5 [1,708.5–2,991.0]
DZ (n) 32 32
Male, n (%) 13 (40.6) 12 (37.5)
Age at sampling (years) 28.00 (18.16) 28.00 (18.16)
Duration of follow-up (years) 19.9 (8.3) 19.8 (8.3)
Age at diagnosis (years) 17.53 (14.45) NA





CML (ng/mL), median [interquartile range] 1,776.5 [1,185.5–2,077.5] 1,616.5 [1,252.0–1,854.0]
Features of MZ and DZ twin pairs discordant for type 1 diabetes including disease duration and results at sampling. Data are means (SD)
unless otherwise indicated. NA, not applicable.
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protein to which the CML is attached. Assay sensitivity was 5 ng CML/mL with
intra- and interassay variability ,4 and ,5%, respectively (18).
Diabetes-associated autoantibody levels or assay
Population study. All subjects were tested for ICA in a single laboratory
(Ulm) by indirect immunoﬂuorescence on unﬁxed sections of human pancreas,
with a detection limit of 5 JDFU and .20 JDFU considered positive (17)
ICA+ subjects were tested for GADA and IA-2A, and 65% of these subjects
were tested for ZnT8A (London, U.K.), using radioimmunoprecipitation assays
(8,10). Ulm assay characteristics were GADA 86% sensitivity and 95% speciﬁcity
and IA-2A 73% sensitivity and 99% speciﬁcity (16). Characteristics of the ZnT8A
assay are described above.
Twin study. All twins were tested for serum autoantibodies to GADA, IA-2A,
and ZnT8A using established radioimmunoprecipitation assays (8,10). All twin
samples were tested at a single laboratory (London) in batched assays with
values expressed as categorical (positive/negative) and continuous traits.
Positive results were duplicated, reducing false positives to ,0.2%. In the
latest Diabetes Antibody Standardization Program (DASP 2008), London
assay characteristics were as follows: GADA sensitivity 90%, speciﬁcity
93%; IA-2A sensitivity 68%, speciﬁcity 95% (19); and ZnT8A sensitivity 60%,
speciﬁcity 88% (M. Hawa, unpublished data).
HLA genotype. HLA class II genotyping was performed in twin (data not
shown) and population studies with sequence-speciﬁc oligonucleotides after
DNA ampliﬁcation with HLA-DRB1– and HLA-DQB1–speciﬁc primers (16).
HLA risk status was deﬁned as a categorical trait (risk/high risk). Carriers of
any of the DRB1*03, DRB1*04, and/or DQB1*302 alleles were considered
high risk.
Statistical analysis
Diabetes prediction. To test whether serum autoantibodies, CML, and HLA
risk status predict type 1 diabetes in 115 ICA+ subjects, we estimated positive
and negative predictive values as well as sensitivity and speciﬁcity of the
markers using the Kaplan-Meier method. Multivariable Cox proportional
hazards models were used to estimate hazard ratios (HR) and 95% CIs ad-
justed for age and sex. Survival time was deﬁned as time from inclusion
(months) to either diagnosis or last follow-up. Variables, irrespective of
statistical signiﬁcance in the univariable analyses, were CML, GADA, IA-2A,
ZnT8A at inclusion, and HLA risk status. Model 1a included the classical risk
factors HLA, GADA, IA-2A, and ZnT8A; model 1b included only CML; model
1c included all factors in models 1a and b; model 1d included only the sig-
niﬁcant predictors of models 1a and b. For models 1a–d, analyses were
performed on case subjects with complete data (n = 73) on all predictors. In
addition, two post hoc models were tested: model 2 included CML at onset
categorized as high (.600 ng/mL) or low (,600 ng/mL) for all 115 ICA+
subjects; model 3 included DCML (CMLlast visit 2 CMLinclusion) calculated for
the 73 subjects from whom serum was available at two different time points.
The proportional hazards assumption was examined using the log-minus-log
plot of the survival function. To assess the overall discriminatory power
for each model, we calculated the concordance (c)-statistic, an index com-
parable to the area under the receiver operating curve. Data handling and
(preliminary) analyses were done with STATA 11.1 (StataCorp, College
Station, Texas). Quantitative genetic modeling was performed using Mx
software (20,21). Variables were natural logarithm transformed if distribu-
tion deviated from normal before statistical analyses. Tests were two-tailed,
and P , 0.05 was considered signiﬁcant.
Twin study. Because twin pairs were initially discordant for diabetes (cotwin
case-control design) matched for age, genes (for MZs completely, for DZs in
part), and shared childhood environmental exposures, paired Student t test
examined differences within twin pairs (i.e., disease effects) after adjustment
for sex. Determinants of CML levels and GADA, IA-2A, and ZnT8A were tested
within a regression framework using generalized estimating equations, which
takes the nonindependency of twin data into account to generate unbiased
P values (20). To estimate the inﬂuence of genetic and environmental factors,
we conducted quantitative genetic model ﬁtting (21). In brief, we compared
covariances (or correlations) in MZ and DZ twin pairs and quantiﬁed sources
of individual differences by separation of observed phenotypic variance into
additive (A) genetic, common (shared) (C), and unique (or nonshared) (E)
environmental components. The signiﬁcance of components A and C was
assessed by testing deterioration in model ﬁt after each component was
dropped from the full model (ACE). Standard hierarchic x2 tests were used
to select the best ﬁtting model in combination with Akaike Information
Criterion (AIC = x22 2 df). Mean levels of CML and GADA, IA-2A, and ZnT8A
were adjusted for age and sex before calculating twin correlations with
residuals used in model ﬁtting.
RESULTS
Population study. Of 115 ICA+ subjects (Table 1), 33
developed type 1 diabetes after follow-up. The follow-up
duration was similar in those who did and did not develop
diabetes (P = 0.14). Compared with subjects who did not
develop diabetes, prediabetic subjects had higher CML
levels both at inclusion (P , 0.001) and at last follow-up
(P , 0.001) even after correction for age and sex (P ,
0.001 for both).
Twin study. In MZ and DZ twin cohorts, serum CML was
not inﬂuenced by age, sex, diabetes status, or disease du-
ration. CML levels were higher in MZ than in DZ twins (P,
FIG. 1. Mean (SD) baseline serum CML in the population and twin study. Graded CML increase in childhood population and adult twins
according to ICA and/or type 1 diabetes (T1D). Control children (n = 2,102) CML mean (SD) [interquartile range] = 458.1 ng/mL (128.4) [372.0–
534.0]; adult twins (n = 168) CML mean (SD) [interquartile range] = 792.2 ng/mL (127.4) [708.5–867.5]). No T1D ICA+ (n = 82); T1D ICA+ (n =
33); no T1D twins = nondiabetic cotwins (n = 64); T1D twins (n = 64). Untransformed CML values are plotted in the ﬁgure; however, all sta-
tistical analyses were performed on natural logarithm–transformed CML values.
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0.001) (Table 2), which we considered in quantitative ge-
netic model ﬁtting analyses. Diabetic twins had similar
serum CML levels compared with their nondiabetic co-
twins, but both were raised compared with normal control
singletons and normal control twins (Fig. 1). Twin corre-
lations for serum CML levels were strong and similar in MZ
and DZ twin pairs (Fig. 2A and B). Model ﬁtting showed
that additive genetic inﬂuences (A) could be dropped from
the full ACE model without deterioration in ﬁt (ACE vs.
CE: Dx2 [df = 1] = 92.57–92.57 = 0, P = NS). Shared envi-
ronment (C) could not be dropped from the model because
the ﬁt deteriorated (ACE vs. AE: Dx2 [df = 1] = 103.64–
92.57 = 11.07, P = 0.001). Thus, the CE model showed the
best ﬁt, conﬁrmed by the lowest AIC. In the best ﬁtting
FIG. 2. Scatterplots of diabetic (twin 1) vs. nondiabetic (twin 2) for natural logarithm–transformed serum CML. Serum CML corrected for age and
sex for MZ (A) and DZ (B) twins shows strong correlations in both MZ (r = 0.81) and DZ (r = 0.69) twins irrespective of disease. (A high-quality
color representation of this ﬁgure is available in the online issue.)
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model, shared environmental factors explained 75% (95%
CI 62–84) of individual differences, with the remainder due
to nonshared environment (25% [16–38]).
Diabetes-associated autoantibodies
Population study. Of the 115 ICA+ subjects, 33 developed
diabetes (Table 1) and compared with those who did not,
were more often positive for GADA (P = 0.04), IA-2A (P ,
0.001), and ZnT8A (P , 0.001). Subjects who developed
diabetes were more often at risk based on their HLA alleles
(P = 0.007).
Twin study. More diabetic twins, compared with their
nondiabetic twins, were GADA, IA-2A, and ZnT8A positive,
irrespective of zygosity. Of 64 twin pairs, 31 diabetic twins
had autoantibodies compared with 9 nondiabetic twins
(P , 0.0001) (Table 2). When analyzed as continuous traits,
diabetic twins, compared with their nondiabetic cotwins,
had higher values for GADA (P = 0.02) and IA-2A (P = 0.001)
but not ZnT8A. Neither age nor disease duration affected
GADA levels, but older subjects had less IA-2A (P , 0.001)
and ZnT8A (P = 0.002). Twin correlations (r) were weak for
GADA, r(MZ) = 20.03, r(DZ) = 0.40; IA-2A, r(MZ) = 0.06,
r(DZ) =20.03; and ZnT8A, r(MZ) = 0.15, r(DZ) = 0.15. Model
ﬁtting showed that for GADA, IA-2A, and ZnT8A, the so-
called E model (including only the unique environmental [E]
variance component) was most parsimonious with best ﬁt.
Diabetes prediction
Population study. Kaplan-Meier survival tables were
used to calculate absolute 10-year risk according to CML
risk status based on the 115 ICA+ subjects. Positive and
negative predictive values, respectively, were as follows:
raised CMLinclusion 52.2 and 82.6% (sensitivity 67.7%, spec-
iﬁcity 72.2%); GADA 36.0 and 86.2% (sensitivity 88.6%,
speciﬁcity 31.3%); IA-2A 54.8 and 81.0% (sensitivity 51.5%,
speciﬁcity 82.9%); and ZnT8A 45.7 and 87.5% (sensitivity
76.2%, speciﬁcity 64.8%). When combining the CML risk
status with each autoantibody status, the accuracy in-
creased since the positive predictive values increased and
the negative predictive values remained stable: GADA 51.4
and 79.5% (positive and negative, respectively) (sensitivity
54.3%, speciﬁcity 77.5%); IA-2A 70.6 and 78.6% (sensitivity
36.4%, speciﬁcity 93.9%); and ZnT8A 62.5 and 79.7% (sen-
sitivity 45.5%, speciﬁcity 88.7%). In Cox proportional haz-
ards models, age or sex did not predict diabetes (Table 3).
Model 1a shows that of the classic risk markers, only ZnT8A
signiﬁcantly contributed to prediction of diabetes. Model 1b
shows that the new marker CMLinclusion signiﬁcantly pre-
dicted diabetes. Robustness analyses using all ICA+ subjects
(n = 115) rather than those with complete marker data (n = 73)
gave comparable results to model 1b (HR 1.003 [95% CI
1.001–1.006]; P = 0.04, Harrell C = 0.73). Testing signiﬁcant
predictors from models 1a and b showed CMLinclusion
and ZnT8A independently predicted diabetes, with a high
c-statistic (model 1d).
Post hoc tests of predictive thresholds. To determine
potential threshold levels for predictive capacity, CML inclusion
was divided into deciles to use as a categorical predictor.
Relative risk of diabetes increased with each decile, but only
the 4 upper deciles contributed substantially to diabetes
prediction (HR 7.05–11.1; P = 0.08–0.03); when categorized
into 4 upper deciles (CMLinclusion .600 ng/mL) and a lower
decile (CMLinclusion ,600 ng/mL), the former had ﬁvefold
diabetes risk (Fig. 3 and model 2 in Table 3). Persistence of
CML levels (i.e., DCML = CMLlast visit 2 CMLinclusion) pre-
dicted diabetes (model 3 in Table 3), reﬂecting the persis-
tent higher CML levels in subjects who developed type 1
diabetes and that CML levels further increased in subjects
who developed type 1 diabetes but decreased in subjects
who did not develop type 1 diabetes.
Twin study. Of 64 nondiabetic twins, 62 (96.9%) had a
raised serum CML (.1,097 ng/mL as 99th centile of normal
twin values), as did 57 (89.1%) of the diabetic twins
(Fig. 1); 10 of 64 had diabetes-associated autoantibodies,
and 2 of these latter 10 subsequently developed diabetes
(Table 2).
DISCUSSION
These observations identify distinct biomarkers, one novel
(serum CML), the other an established disease predictor
(diabetes-associated autoantibodies), which are now shown
to have strong additive and quantitative predictive value in
a large population study. Using the markers at inclusion
only, an optimally predicting model consisted of CML and
ZnT8A with reasonable discriminatory power. Studying
a selected twin cohort excluded genetic factors as sole
determinants of both serum CML levels and serum di-
abetes-associated autoantibodies. It follows that non-
genetic, most probably environmental, factors contribute
to these diabetes-associated features, where the term
environmental represents all nongenetic contributions to
the variation in a trait, whether internal or external to the
TABLE 3
Prediction models for developing type 1 diabetes in the population
study
n HR [95% CI] P value Harrell C
Model 1a
HLA risk 73 2.12 [0.58–7.72] 0.25 0.73
GADA 1.24 [0.33–4.65] 0.75
IA-2A 1.44 [0.60–3.47] 0.41
ZnT8A 3.10 [1.01–9.53] 0.048
Model 1b
CMLinclusion 73 1.005 [1.002–1.007] 0.001 0.67
Model 1c
CMLinclusion 73 1.003 [1.0003–1.006] 0.03 0.74
HLA risk 1.82 [0.50–0.62] 0.36
GADA 1.20 [0.33–4.35] 0.78
IA-2A 1.38 [0.56–3.41] 0.48
ZnT8A 2.45 [0.77–7.76] 0.13
Model 1d
CMLinclusion 73 1.003 [1.0006–1.006] 0.73
ZnT8A 3.04 [1.05–8.80] 0.04
Model 2
CMLinclusion
(high/low) 115 4.98 [2.25–10.99] ,0.001 0.66
Model 3
DCML 73 1.005 [1.003–1.008] ,0.001 0.76
Results of different risk factors using multivariable Cox proportional
hazards models. Serum CML when high at inclusion in study or
change in CML during study were best predictors, and only CML
and ZnT8A independently predicted type 1 diabetes. All models in-
cluded age and sex. Model 1a included the classical risk factors HLA,
GADA, IA-2A, and ZnT8A; model 1b included only CML; model 1c
included all factors in models 1a and b; model 1d included only the
signiﬁcant predictors of models 1a and b. For models 1a–d, analyses
were performed on cases with complete data (n = 73) on all predic-
tors. In addition, two post hoc models were tested: model 2 included
CML at onset categorized as high (.600 ng/mL) or low (,600 ng/mL)
for all 115 ICA+ subjects; model 3 included DCML (CMLlast visit 2
CMLinclusion) calculated for the 73 subjects from whom serum was
available at two different time points.
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individual. Our study indicated that familial (that is, shared)
environmental factors are important determinants of serum
CML levels, while nonshared environmental factors are im-
portant determinants of autoantibody frequency. It follows
that these predictive biomarkers are largely determined by
distinct environmental effects.
Despite the limited heritability of serum CML and diabetes-
associated autoantibodies, in this highly selected cohort of
discordant twins, these two factors are likely to be inﬂu-
enced by genetic factors. For example, additive genetic effects
(heritability) explained 74% of normal population variance in
serum CML (14). Previous twin studies of diabetes-associated
autoantibodies also support a genetic inﬂuence, though
one such study examines only nondiabetic twins without
matching them (8,9). In family studies, those with high-risk
HLA genes show diabetes-associated autoantibodies earlier,
while ZnT8A is associated with speciﬁc genetic susceptibility
(7,22). Nevertheless, the risk of autoantibodies appearing is
inﬂuenced by dietary modiﬁcation in infancy (23,24). HbA1c
(available for 108 of 115 ICA+ subjects), however, was not
associated with CML (data not shown), replicating results
reported in healthy twins (14). Raised serum CML emerges
as a novel and potent biomarker of diabetes risk—a pre-
dictive effect most marked at the highest serum CML levels.
In this quantitative predictive effect, CML resembles auto-
antibodies that are most predictive at high titers and in
combination with other autoantibodies (25).
This study has limitations. Because our patient cohort
was composed exclusively of Caucasian participants,
generalization to other ethnic groups is not possible. Both
serum CML and diabetes-associated autoantibodies are
likely to be only surrogate markers of putative destructive
innate and adaptive immune changes, respectively. A twin
study should ideally be performed prospectively in a pop-
ulation-based cohort from birth to determine the rate of
induction of autoantibodies and diabetes, and because our
twins were initially disease discordant, disease concor-
dance rate is underestimated (26), but our analysis limits
bias from the strong disease association with these auto-
antibodies (2). If autoantibodies were genetically de-
termined, even nondiabetic MZ twins would eventually
show them, which, in general, they did not. While we noted
higher CML levels in twins, it would not affect our in-
terpretation of the results, though it could be due to dif-
ferences between the Ulm population study and the U.K.
twin study in subjects’ age and diabetes duration and dif-
ferences in sample storage (280 and 230°C, respectively).
Furthermore, the cause of the raised serum CML, and its
relationship to the origin of diabetes, is unclear, though
a dietary source is most likely, consistent with a shared
familial origin irrespective of zygosity (13). Speciﬁcally,
thermally sensitive nutrients, including infant formula
cow’s milk and heat-treated animal fat, are major sources
of AGEs, and AGEs, including CML, can reach adult se-
rum levels by 1 year of age and have been implicated in
sustaining an altered inﬂammatory response (13). Indeed,
while we found raised AGE levels, in the form of serum
CML, in young children before the onset of type 1 di-
abetes, AGE levels also increase with age and disease
duration and are associated with diabetes complications
(18). Different AGEs and different AGE receptors are
responsible for their inﬂammatory action, and further
studies will be required to deﬁne which are involved in
the prediabetic process (e.g., increase in the AGE serum
carboxyethyl-lysine is associated with relapses in multi-
ple sclerosis) (27,28).
The present observations, which imply that at least two
distinct environmental events cause type 1 diabetes, could
consolidate different theories regarding the pathogenesis
of autoimmune diabetes (e.g., hygiene hypothesis and
FIG. 3. Kaplan-Meier survival curves for type 1 diabetes (T1D) risk based on baseline CML levels. Subjects in the upper 4 deciles of the CML
distribution were found to have high risk and subjects in the bottom 6 deciles low risk of developing T1D. The curves plotted in the ﬁgure are
a graphic representation of the analysis presented in Table 3, model 2 (n = 115). (A high-quality color representation of this ﬁgure is available in
the online issue.)
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accelerator hypothesis), as well as different schools of
opinion regarding candidate environmental agents (e.g.,
enteroviruses and diet) (1–3,13). That only two biomarkers
(serum levels of a proinﬂammatory AGEs and diabetes-
associated autoantibodies) can predict most children who
develop diabetes suggests that there may be a ﬁnite number
of critical environmental factors causing the disease. Wean-
ing to a highly hydrolyzed casein formula in place of con-
ventional cow’s milk–based formula recently has been
shown to reduce the frequency of appearance of diabetes-
associated autoantibodies (24). The potent predictive value
of the AGE biomarker in this present study, supported by
another recent study, raises the possibility that dietary
modiﬁcations in early life to reduce AGE intake could
prevent progression to type 1 diabetes (29). Furthermore,
reduction of AGEs by diet or drug therapy in animal models
of autoimmune diabetes reduces not only AGE levels but
also progression to diabetes (30).
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